The QualityStocks Daily Friday, November 9th, 2018

Today's Top 3 StockMarketWatch

BUYINS.NET (NVLN) +36.80%

StreetInsider (TWST) +31.58%

The Street (REV) +31.24%

The QualityStocks Daily Stock List

First Choice Healthcare Solutions, Inc. (FCHS)

First Penny Picks, Marketbeat, 007 Stock Chat, PennyStockSpy, Greenbackers, StocksImpossible, TheMicrocapNews, and OTCBB Journal reported earlier on First Choice Healthcare Solutions, Inc. (FCHS), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

First Choice Healthcare Solutions, Inc. (FCHS) engages in owning and operating multi-specialty (non-physician-owned) medical centers of excellence across the southeastern United States. The Company is one of the nation's only non-physician-owned, publicly traded healthcare services enterprises focused on the delivery of complete musculoskeletal solutions with an emphasis on Orthopaedic and Spine care. FCHS has its headquarters in Melbourne, Florida. The Company’s shares trade on the OTC Markets Group’s OTCQB.

FCHS’ flagship integrated platform administers more than 100,000 patient visits each year. The platform consists of First Choice Medical Group, The B.A.C.K. Center, and Crane Creek Surgery Center. FCHS medical centers of excellence focus on treating patients in diverse specialties. These include Orthopaedics, Spine Surgery, Neurology, Interventional Pain Management, and related diagnostic and ancillary services.

First Choice Medical Group (Melbourne, Florida) is the Company’s flagship multi-specialty medical center of excellence. First Choice Medical Group specializes in the delivery of musculoskeletal medicine and rehabilitative care with numerous quality-focused objectives centered on enriching its patients’ care experience.

FCHS has expanded its portfolio of Medical Centers of Excellence in the Florida Space Coast region with its Brevard Orthopaedic Spine & Pain Clinic, Inc. (d/b/a The B.A.C.K. Center). The B.A.C.K. Center is a foremost, advanced orthopaedic spine and pain practice in Brevard County, Florida.

FCHS’s Crane Creek Surgery Center is an AAAHC accredited facility. Its commitment is to deliver first-class, ambulatory surgical care in a convenient, comfortable outpatient environment. The 18,000-plus sq. ft. facility is in Melbourne, Florida within the Crane Creek Medical Center building. In addition, this building is home to The B.A.C.K. Center.

Yesterday, First Choice Healthcare Solutions (FCHS) reported its financial results for the three and nine month periods ended September 30, 2018. Total Revenue grew 26 percent to $9.7 million quarter over quarter and 3.0 percent sequential increase over the prior quarter.

Net Income improved by $176,811 to ($263,587) quarter over quarter. Loss was affected by unusual expenses of $230,000 because of exploring strategic initiatives. The Company stated that Crane Creek Surgery Center continues to improve with Q3 Net Income of $232,807, versus a Net Loss of $184,924 quarter over quarter. Moreover, year-to-date surgeries increased 17.2 percent to 2,795.

Chris Romandetti, FCHS’ President and Chief Executive Officer, stated, “For the third quarter we are please to report net patient service revenue of approximately $9.1 million, a 28 percent increase over prior year. We are pleased to report that our ancillary services continue to show strength across the board, with PT visits and imaging increasing 63 percent and 69 percent, respectively.”

First Choice Healthcare Solutions, Inc. (FCHS), closed Friday's trading session at $1.09, up 2.83%, on 10,500 volume with 19 trades. The average volume for the last 3 months is 12,264 and the stock's 52-week low/high is $0.91/$1.46.

chart

RenovaCare, Inc. (RCAR)

NetworkNewsWire, Zacks, The Street, StockInvest.us, Business Wire, Barchart, 4-Traders, Stockhouse, InvestorsHub, OTC Markets, Insider Financial, Finance Registrar, Emerging Growth, Market Exclusive, The Biotech Investor, GuruFocus, BioPortfolio, Street Insider, Capital Cube, Advanced Equity Research, Wallet Investor, MarketWatch, and Insider Financial reported on RenovaCare, Inc. (RCAR), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

RenovaCare, Inc. is developing first-of-their-kind autologous (self-donated) stem cell therapies for the regeneration of human organs. The Company’s first product under development targets the body’s largest organ, the skin. RenovaCare is the developer of the patented CellMist™ and SkinGun™ technologies. These are for isolating and spraying a patient’s own stem cells onto burns and wounds for quick self-healing. RenovaCare is headquartered in Pittsburgh, Pennsylvania.

RenovaCare’s flagship technology, the CellMist™ System, uses its patented SkinGun™ to spray a liquid suspension of a patient’s stem cells – the CellMist™ Solution – onto wounds. The Company is developing its CellMist™ System as a promising new option for patients suffering from burns, chronic and acute wounds, and also scars.

The CellMist™ System targets patients who suffer burns, chronic and acute wounds, acne scarring, and skin defects and diseases such as vitiligo. Based on preliminary case studies, CellMist™ System patients can be treated within 90 minutes of entering an emergency room. A patient’s stem cells are isolated, processed, and sprayed onto wound sites for fast healing.

Skin stem cells sprayed with the patented SkinGun™ device maintain 97.3 percent cell viability. There is no impairment to cell growth or metabolic activity when evaluated in vitro. Last year, RenovaCare miniaturized the SkinGun™ from the size of a microwave to a device that fits comfortably in one hand.

In investigative clinical use in the United States, SkinGun™ treatments have shown the potential to naturally and quickly heal burns and other serious wounds. The CellMist™ System harvests a patient’s stem cells from a small area of skin, typically around 1 square inch. It suspends them in the water-based CellMist™ Solution. The suspension is delicately sprayed onto the wound utilizing the SkinGun™ deposition device, where it starts to grow new skin at the cellular level.

In February of this year, RenovaCare announced new initiatives to expand its product pipeline and associated clinical indications beyond severe second-degree burns. Its expansion program follows earlier patent awards and positive Food and Drug Administration (FDA) feedback on its pioneering stem cell spray technology.

The Company stated that it has been working to invent and develop new products and methods. This includes first-generation prototypes. Clinical protocols for a number of new indications, where a patient’s own stem cells can be harvested and sprayed or otherwise applied to attain fast scar-free healing, will undergo development, and intellectual property (IP) will be expanded accordingly.

RenovaCare, Inc. (RCAR), closed Friday's trading session at $1.59, up 3.92%, on 9,899 volume with 27 trades. The average volume for the last 3 months is 25,526 and the stock's 52-week low/high is $1.18/$12.82.

chart

Bionik Laboratories Corp. (BNKLD)

NetworkNewsWire, Street Insider, Marketbeat, InvestorsHub, Stockhouse, Barchart, Market Exclusive, Zacks, MarketWatch, 4-Traders, Equities, Wallet Investor, and OTC Markets reported earlier on Bionik Laboratories Corp. (BNKLD), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Bionik Laboratories Corp. is a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home. Via the acquisition of Interactive Motion Technologies, it has added a portfolio of products centered on upper and lower extremity rehabilitation of stroke patients and other mobility-impaired patients. Bionik Laboratories has is head office in Toronto, Ontario. The OTCQB-listed Company has its U.S. headquarters in Watertown, Massachusetts.

Bionik Laboratories fully integrated Interactive Motion Technologies, Inc. into the Company following the May 2016 acquisition. Bionik has three products available on the market and four products in varied stages of development. The design of the InMotion Systems - the InMotion ARM™, InMotion HAND™, InMotion ANKLE™, and InMotion WRIST™ are to provide intelligent, patient-adaptive therapy in a way that has been clinically verified to maximize neuro-recovery.

The InMotion ARM is an evidence based intelligent, interactive rehabilitation technology. It senses patient movements and limitations, providing assistance-as-needed™ in real-time. The InMotion HAND is an add-on module to be used with the InMotion ARM™. These two work together to provide assist-as-needed™ support for reaching with grasp and release movements, or independently for focused training on individual hand movements.

The InMotion WRIST is an evidence based and research proven interactive rehabilitation device. InMotion WRIST senses patient movements and limitations. In addition, it provides assistance-as-needed™. It can accommodate the range of motion of a normal wrist in daily tasks. InMotion WRIST can be used by clinicians as a stand-alone treatment option or in addition to the InMotion ARM.

Furthermore, Bionik is developing a lower-body exoskeleton, ARKE™. The design of ARKE™ is to allow paraplegics and other wheelchair users the ability to rehabilitate through walking. Moreover, the Company has launched the next-generation InMotion™ Arm. It launched its next-generation InMotion Arm interactive robotic system for the clinical rehabilitation of stroke survivors and those with mobility impairments due to neurological conditions. The improved new generation InMotion Arm will provide the same innovative active-assisted robotic therapy.

In October, Bionik Laboratories announced it entered into a purchase order with Clinique Les Trois Soleils in Boissise-le-Roi, France for Bionik’s InMotion Arm™ robot. Clinique Les Trois Soleils provides versatile and comprehensive rehabilitation programs for patients recovering from orthopedic, musculoskeletal or neurological injuries.

Dr. Eric Dusseux, Chief Executive Officer and Director of Bionik Laboratories, said, "We are excited to continue our terrific collaboration with Clinique Les Trois Soleils for another InMotion Arm™ robotic system. While developing new business pipelines is a priority, we are pleased to serve current customers through the purchase of additional units. We believe that the continued selection of BIONIK's InMotion Arm™ by Clinique Les Trois Soleils validates to the European market that our technology is best positioned to provide optimal patient outcomes and become an integral part of a neurological therapy regimen."

Bionik Laboratories Corp. (BNKLD), closed Friday's trading session at $6.00, up 100.00%, on 505 volume with 9 trades. The average volume for the last 3 months is 301 and the stock's 52-week low/high is $3.00/$27.375.

chart

Voip-Pal.com, Inc. (VPLM)

SmallCapVoice, SmallCapAllStars, FeedBlitz, TheSUBWAY, Stock Twiter, Pumps and Dumps, Equities, VC Stock Marketing, Clutch Investments, Equities Canada, TryBestPennyStocks, Buzz Stocks, and UndiscoveredEquities reported on Voip-Pal.com, Inc. (VPLM), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Voip-Pal.com, Inc. owns a portfolio of patents relating to Voice-over-Internet Protocol (VoIP) technology. The OTCQB-listed Company is now looking to monetize its fundamental patents by way of a sale or licensure of its technology. In December 1997, Voip-Pal.com incorporated in the State of Nevada. In 2013, it acquired Digifonica International (DIL) Limited to fund, co-develop, and complete Digifonica's patent collection. Voip-Pal.com has its corporate office in Bellevue, Washington.

Voip-Pal’s Intellectual Property (IP) value comes from manifold issued US Patent and Trademark Office (USPTO) patents. This includes five parent patents, one of which is foundational and the others that build upon the former. The five core patents are: Routing, Billing & Rating (RBR); Lawful Intercept; Enhanced E-911; Mobile Gateway; and Uninterrupted Transmission.  

Voip-Pal.com’s patented technology provides Universal numbering ubiquity; network value as defined by Metcalfe; the imperative of interconnect, termination, and recompense for delivery of calls by other networks; and regulatory compliance in regulated markets. Additionally, the Company’s patented technology provides interconnection of VoIP networks to mobile and fixed networks; and maintenance of uninterrupted VoIP calls across fixed, mobile, and Wi-Fi networks.  

Voip-Pal believes that its Lawful Intercept patents could prove to be a vital tool for law enforcement in its efforts to combat crime and stop terror attacks. The technology provides the means for judicially authorized covert intercept of any kind of communications sent through VoIP. This includes voice calls, media, as well as messaging.

The Company’s U.S. patent portfolio has grown from five core patents to 20 issued patents or allowed applications, and a number of pending patent applications in different stages of examination at the USPTO. The most recent addition to the U.S. patent portfolio is U.S. Patent No. 9,998,363, issued June 12, 2018. It relates to allocating charges for communications services. Also, Voip-Pal owns issued patents and/or pending patent applications in Canada, Europe, India, Indonesia, and Brazil. On May 30, 2018, Voip-Pal was granted European Patent No. 2,084,868 for its communications/routing technologies.

Voip-Pal.com, Inc. (VPLM), closed Friday's trading session at $0.07, up 1.30%, on 290,341 volume with 24 trades. The average volume for the last 3 months is 639,522 and the stock's 52-week low/high is $0.0162/$0.4499.

chart

InterCloud Systems, Inc. (ICLD)

INO.com Market Report, BUYINS.NET, GreatStockPix, Street Insider, Microcapmillionaires, PennyPro, Promotion Stock Secrets, Marketbeat.com, Broad Street, StocksImpossible, OTCBB Journal, Stock Onion, Stock Tips Network, Buzz Stocks, Greenbackers, Jason Bond, RedChip, Wealthpire Inc., PennyStockProphet, Penny Pick Finders, Planet Penny Stocks, Hit and Run Candle Sticks, and Investing Futures reported previously on InterCloud Systems, Inc. (ICLD), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

InterCloud Systems, Inc. is a leading provider of cloud networking orchestration and automation solutions and services. The Company provides the modern-day Information Technology (IT) and network solutions to the enterprise markets via cloud computing and professional services. InterCloud provides cloud services (SaaS, PaaS, and IaaS), professional consulting, data solutions, and maintenance services.

Established in 2006, the Company’s mission is to enable carriers to speed up the installment of Virtualized Network and IT Services. InterCloud Systems is based in Shrewsbury, New Jersey. The Company lists on the OTC Markets Group’s OTCQB.

InterCloud is a top provider of cloud networking orchestration and automation for Software Defined Networking (SDN) and Network Function Virtualization (NFV) cloud environments. The Company is a provider to the telecommunications service provider (carrier) and corporate enterprise markets.

The Company’s cloud solutions provide enterprise and service-provider customers the opportunity to adopt an operational expense model through outsourcing cloud deployment and management to InterCloud Systems.

InterCloud’s products and solutions include NFVGrid – NFVO Management & Analytics Platform. This is a full scale next generation networking platform for virtualized network functions. NFVGrid is proprietary IP. However, NFVGrid completely embraces Open Source.

InterCloud Systems’ solutions include Disaster Recovery. The Company’s cloud backup permits one to backup their vital business data to a remote and secure location for quick disaster recovery.

Regarding its Professional Services, InterCloud Systems has a 24×7 practice for numerous technologies. These includeUnix / Linux System Administration; Microsoft System Administration; VMware Administration; and ​ Open Stack / Cloud Stack. These additionally include Juniper Design, Operate & Support; ​ Cisco Design, Operate & Support; as well as Citrix Design, Operate & Support.

Recently, InterCloud Systems announced that its Netlayer.io software platform became a technology partner with Computer Associates (CA). Netlayer.io was recently chosen by CA as a Technology Partner. The integrated solution was presented at the CA World convention, which took place in Las Vegas, Nevada in November 2017.

Netlayer.io integrates with CA’s network monitoring and analytical systems. The integrated Netlayer.io/CA solution provides end-to-end orchestration and monitoring functions for next-generation virtualized networking environments. This includes SDN, NFV, as well as SD-WAN.

CA monitoring and analytics by way of Netlayer.io's orchestration permits reactive and proactive actions founded on CA's analytics input.

InterCloud Systems, Inc. (ICLD), closed Friday's trading session at $0.00146, up 4.29%, on 11,080,561 volume with 98 trades. The average volume for the last 3 months is 13,379,652 and the stock's 52-week low/high is $0.001/$0.92.

chart

Kitov Pharmaceuticals Holdings Ltd. (KTOV)

Investing.com and MarketWatch reported on Kitov Pharmaceuticals Holdings Ltd. (KTOV), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

A biopharmaceutical drug development company, Kitov Pharmaceuticals Holdings Ltd.’s veteran team of healthcare professionals maintains a proven record of accomplishment in streamlined end-to-end drug development and approval. Its team takes advantage of deep regulatory and clinical-trial expertise. Kitov Pharmaceuticals’ flagship combination drug is KIT-302. The intention of this drug is to treat osteoarthritis pain and hypertension at the same time. Kitov Pharmaceuticals Holdings has its corporate office in Tel Aviv, Israel.

KIT-302 attained the primary efficacy endpoint for its Phase III clinical trial. The Company’s newest drug is NT219. This drug is developed by Kitov’s majority-owned subsidiary; TyrNovo Ltd. TyrNovo is a privately-held developer of novel small molecules in the oncology therapeutic arena.

KIT-302 consists of two Food and Drug Administration (FDA)-approved drugs. One is celecoxib (the active ingredient in Pfizer’s Celebrex®) for the treatment of pain caused by OA. The other is amlodipine besylate (the active ingredient in Pfizer’s Norvasc®), a drug designed to treat hypertension. Kitov Pharmaceuticals submitted a new drug application (NDA) for marketing approval of KIT-302 with the FDA in July of this year.

NT219 is a small molecule. It presents a new concept in cancer therapy. In combination with different approved oncology drugs, it demonstrated potent anti-tumor effects and increased survival in various cancer models. NT219 promotes the degradation and the phosphorylation of two oncology-related checkpoints, Insulin Receptor Substrates (IRS) 1 and signal transducer and activator of transcription 3 (STAT3), respectively.

NT219 activates the "OFF" switch, extensively blocking major oncogenic pathways. Targeted anti-cancer drugs inhibit the "ON" signal. Results from pre-clinical studies of NT-219 demonstrated its efficacy in overcoming drug resistance in an array of cancers and in combination with multiple pharmacologic cancer therapies. The Company is concentrating on advancing this highly promising therapeutic candidate into clinical trials in 2018. This is to provide enhanced treatment options to cancer patients.

This month, Kitov Pharmaceuticals Holdings announced the acquisition of an additional 27 percent stake in TyrNovo Ltd. from unaffiliated minority shareholders. Kitov Pharmaceuticals (as announced on January 13, 2017) had acquired a controlling interest that is now roughly 65 percent of TyrNovo. After the closing of this transaction, Kitov Pharmaceuticals will hold about 92 percent of TyrNovo's issued and outstanding ordinary shares.

TyrNovo is developing NT219, a small molecule originally developed by Dr. Hadas Reuveni and Prof. Alexander Levitzki at the Hebrew University. NT219 is exclusively licensed from Yissum, the Hebrew University Research Development Company.

In addition, this month, Kitov Pharmaceuticals announced that the FDA filed the Company's New Drug Application (NDA) for KIT-302, its lead drug candidate. Therefore, the FDA accepted the NDA for a full review.

Mr. J. Paul Waymack, M.D., Sc.D., Kitov Pharmaceuticals’ Chairman of the Board and Chief Medical Officer, stated, "The acceptance of filing of our NDA for KIT-302 represents a key achievement toward commercialization of our lead drug candidate. We intend to work closely with FDA as it reviews the NDA. We look forward to FDA rendering a decision on approval for marketing of KIT-302 during the second quarter of 2018."

Kitov signed a definitive License Agreement for KIT-302 for the territory of South Korea with Kuhnil Pharmaceutical Co. Ltd. Kuhnil Pharmaceutical is a foremost South Korea-based pharmaceutical enterprise. Furthermore, Kitov completed recruitment of its renal function clinical trial to demonstrate the beneficial effects of KIT-302 on kidney function.

Kitov Pharmaceuticals Holdings Ltd. (KTOV), closed Friday's trading session at $1.33, off by 2.21%, on 43,725 volume with 102 trades. The average volume for the last 3 months is 81,183 and the stock's 52-week low/high is $1.24/$3.81.

chart

Innovative Designs, Inc. (IVDN)

Greenbackers, Pennybuster, and PennyStocks24 reported earlier on Innovative Designs, Inc. (IVDN), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Innovative Designs, Inc. manufactures Insultex® House Wrap, the Arctic Armor® Line, hunting apparel, swimwear, wind shirts, jackets, and the multi-function "All in One" under the "IDI Gear" label featuring Insultex®. All of its products contain Insultex®. The Company’s products deliver premier warmth and comfort with insulating, windproof, as well as waterproof protection. Insultex® is the lightest and thinnest thermal insulation. Established in 2002, Innovative Designs is based in Pittsburgh, Pennsylvania.

Since its establishment, Innovative Designs has centered its efforts on completing the development, design, and prototypes of its products, and obtaining retail stores or sales agents to offer and sell its products. The Company primarily sells its products via agencies, distributors, independent sales agents, retailers, and a Website in the United States and Canada.

Additionally, the Company has concentrated its efforts on developing its website to sell more of its products, and on establishing distribution channels for its House Wrap® product.

Arctic Armor™ by IDI Gear is a 100 percent waterproof and windproof breathable nylon shell with Insultex® Thermal Insulation. The Company offers the Arctic Armor™ Suit. Each Arctic Armor™ suit uses three layers of its exclusive thermal insulator Insultex®. Moreover, Innovative Designs offers the Arctic Armor™ Ice Fishing Suit. The Company can also supply national home builders with its Insultex® House Wrap.

An example of Innovative Designs’ clothing products is its “Arctic Armor Extreme Cold Base Layer Shirt”. This shirt is 68.5 percent Thermo Cool Polyester and 31.5 percent Bamboo Charcoal. It is highly breathable and the wicking yarn keeps one comfortable and dry. It is ion-treated to promote oxygen uptake. It is also UV stable, and anti-static. The shirt also has anti-microbial technology to control odor.

Insultex® is the newest thermal insulation on the market. The material can be used in outerwear, gloves, hats, pants, tents, sleeping bags, coolers, boots, swimsuits, blankets, comforters, and other items.

Insultex® incorporates countless micro air cells. These individual pockets trap air and do not allow it to escape. This is the key to keeping people warm. Insultex® directly reflects the body’s radiant heat back to the body. Insultex® is windproof, waterproof, and buoyant.

This past June, Innovative Designs announced that it entered into a sales agreement with New Thinking Fashion USA, Inc. New Thinking Fashion USA specializes in the sale of finished fabrics to a broad assortment of apparel manufacturers. It will present Insultex™ to several of their present clients. New Thinking Fashion USA is a multilevel selling organization in the heart of the garment district on West 38th Street, New York, New York.

Also in June, Innovative Designs, in an attempt to grow its worldwide business, entered into a 2 year agreement with Epoch Consultants LLC, who has been granted exclusive rights in India. Epoch Consultants will be conducting marketing of Insultex™ to apparel manufacturers and the Indian military.

Innovative Designs, Inc. (IVDN), closed Friday's trading session at $0.24, up 20.00%, on 20,027 volume with 8 trades. The average volume for the last 3 months is 5,072 and the stock's 52-week low/high is $0.16/$0.75.

chart

Lightwave Logic, Inc. (LWLG)

FeedBlitz, SmallCapVoice, PennyStocks24, SmallCap Fortunes, StockGuru, OTC Picks, Standout Stocks, and HotOTC reported previously on Lightwave Logic, Inc. (LWLG), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Lightwave Logic is a technology business concentrating on the development of Next Generation Photonic Devices and Non Linear Optical Polymer Materials Systems for applications in high-speed fiber-optic data communications and telecommunications. The Company creates prototype electro-optic demonstration devices. Lightwave Logic is based in Longmont, Colorado and the Company lists on the OTC Markets’ OTCQB.

Lightwave Logic is moving toward commercialization of next generation photonic devices utilizing its high-activity and high-stability organic polymers for applications in data communications and telecommunications markets. The Company is using organic nonlinear electro-optical and all-optical polymers (plastic) as the foundation for a series of proprietary (internal and licensed to external partners) advanced Integrated Optical Devices that have wide-ranging application in telecommunications, data communications, and optical computing for use in commercial and military markets.

Lightwave Logic has integrated its proprietary Perkinamine™ chromophore technology with other chromophores based in part on elements of proprietary, in-licensed technologies. This has resulted in a strong and durable nonlinear organic electro-optical (EO) material, which will be used in photonic device development. It is founded on the Company’s multi-chromophore approach that enables two or more chromophores to work together.

The Company’s Polymer Photonics Integrated Circuit (P2ICTM) is analogous to an electronic integrated circuit. However, it incorporates two or more optical functions or devices integrated onto a single substrate platform. Lightwave Logic’s expectation is that P2ICsTM will become a vital engine in the transceiver market over the next decade.

Lightwave Logic announced in September of 2017 that it achieved outstanding performance of its ridge waveguide Mach-Zehnder modulators ahead of schedule, with bandwidth performance levels that will enable 50Gbps modulation in fiber-optic communications. This important achievement will allow users to use arrays of 4 x 50Gbps polymer modulators using PAM-4 encoding to access 400Gbps data rate systems.

Lightwave Logic’s Intellectual Property (IP) has expanded considerably over the last year. The Company is developing its P2IC into prototypes. It filed more than 6 patents during 2017. It is readying several other inventions for formal filing--most likely early this year.

The Company expects to continue innovating with its P2IC platform this year. It also expects to at least maintain this level of invention during the whole of 2018. In total, Lightwave Logic’s patent portfolio comprises 13 granted patents. These include 4 from the United States, 1 from Canada, 5 from the European Union (EU), 2 from Japan, and 1 from China.  

Lightwave Logic, Inc. (LWLG), closed Friday's trading session at $0.978, up 5.16%, on 58,735 volume with 35 trades. The average volume for the last 3 months is 69,090 and the stock's 52-week low/high is $0.85/$1.50.

chart

Innovative Food Holdings, Inc. (IVFH)

The Bowser Report, Marketbeat.com, Stock Guru, and FeedBlitz reported earlier on Innovative Food Holdings, Inc. (IVFH), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Innovative Food Holdings, Inc. is an industry leading specialty food platform. The Company, through its subsidiaries, is a foremost nationwide provider of direct from source specialty foods, healthcare foods, gluten free foods, and artisanal foods, to the professional foodservice market. Perishable product is delivered direct to the Company’s kitchen the next day via overnight delivery. Non-perishable product is delivered direct to customers. Innovative Food Holdings is headquartered in Bonita Springs, Florida.

For Chefs (Chef Direct), the Company’s vertically-integrated platform enables it to source 7,000-plus specialty foods from around the world and deliver within 24-72 hours. Innovative Food Holdings’ subsidiaries include Artisan Specialty Foods and Innovative Gourmet.

Artisan Specialty Foods is a nationwide specialty food distributer, re-packer, and importer. Artisan serves hundreds of customers in the Chicago area. Additionally, it serves as a nationwide fulfillment center for other Innovative Food Holdings subsidiaries operating in the foodservice and direct-to-consumer markets.

In the direct-to-chef foodservice market, available products include origin specific seafood, exotic meats and game, dry-aged meats, exotic fruits and vegetables, specialty chocolates, artisanal cheeses, and imported specialties. In addition, available products include caviar, wild and cultivated mushrooms, micro-greens, heirloom and baby produce, organic farmed and manufactured food products, estate-bottled olive oils, aged vinegars, and healthcare food products.

Innovative Food Holdings supplies chefs with unique, organic, sustainable, and artisanal products sourced from all areas internationally. The Company markets its products directly to the consumer, by way of its website at www.forthegourmet.com/.

The Company serves restaurants, hotels, country clubs, national chain accounts, casinos, and catering houses. Many of its products are used each day by a host of some of the top professional chefs throughout the United States.

At the end of January 2018, Innovative Food Holdings announced that its subsidiary, Innovative Gourmet, acquired substantially all the assets of one of North America’s top online gourmet food and gift retailers. The business will operate under igourmet’s valued and trusted trade name.

Mr. Sam Klepfish, Innovative Food Holdings’ Chief Executive Officer, said, “The acquisition of igourmet’s business is synergistic to our current mission of providing small specialty food companies direct access to the kitchens of end users nationwide. Our professional management systems will benefit igourmet and they will serve as an additional distribution center for us.”

igourmet offers a broad variety of high quality gourmet and specialty food products by way of www.igourmet.com, and via a full line of omnichannel partners. Furthermore, igourmet offers an extensive array of specialty food products to restaurants, specialty retailers and other business establishments through its specialty foodservice division.

Innovative Food Holdings, Inc. (IVFH), closed Friday's trading session at $0.623, up 0.48%, on 5,026 volume with 5 trades. The average volume for the last 3 months is 71,338 and the stock's 52-week low/high is $0.509/$1.379.

chart

Ipsidy, Inc. (IDTY)

Proactive Investors, Barchart, Stockwatch, Simply Wall St, OTC Markets, Stockhouse, 4-Traders, Investors Hangout, InvestorsHub, Investopedia, TradingView, and Penny Stock Hub reported on Ipsidy, Inc. (IDTY), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Ipsidy, Inc. is a provider of secure, biometric identification, identity management and electronic transaction processing services. The Company’s identity transaction platform creates a trusted transaction, embedding authenticated identity and event details with a digital signature and using a participant's mobile device to approve everyday transactions. OTCQB-listed, Ipsidy has its headquarters in Long Beach, New York.

Established in 2009, the Company previously went by the name ID Global Solutions Corporation. It changed its name to Ipsidy, Inc. in February of 2017. Ipsidy has two operating subsidiaries: MultiPay in Colombia, (www.multipay.com.co); and Cards Plus in South Africa, (www.cardsplus.co.za).

The Company’s platform is undergoing design to use biometric and multi-factor identity management solutions intended to support a broad array of electronic transactions. Ipsidy’s belief is that it is vital that businesses and consumers know who is on the other side of an electronic transaction and have an audit trail, proving that the identity of the other party was properly authenticated.

Fundamentally, Ipsidy’s identity transaction platform aims to help the Company’s customers more quickly and effectively secure their citizens, employees, customers and associated physical and digital transactions, and also promote a more secure, internationally connected world. Ipsidy’s identity platform enables mobile users to more easily authenticate their identity to a mobile phone or portable device of their choosing.

In early March, Datapro, Inc. and Ipsidy announced that they intend to offer IdLok™, Ipsidy's biometric, multi-factor, identity authentication service to Datapro's financial institutions throughout the Latin American marketplace. Datapro is a developer of advanced software systems for financial institutions.

Datapro and Ipsidy entered into a non-binding summary of terms. Moreover, subject to concluding a definitive agreement and technical implementation, Datapro intends to offer IdLok as part of its e-IBS core banking solution for its clients in Latin America. This is to enhance security and efficiency for online account access.

Also this month, Ipsidy announced that it signed a contract for the supply of the de-duplication hardware and software solution consisting of an Automated Fingerprint Identification System (AFIS) with the Zimbabwe Electoral Commission (ZEC) for use in the forthcoming 2018 Zimbabwe General Elections. Ipsidy’s system will be used by the ZEC to produce the required voter rolls from its national biometric voter database, which was established during the past year.

Ruta Amiga S.A.S. and Ipsidy have contracted to launch Ruta Amiga's new loyalty rewards program throughout the Republic of Colombia. Ruta Amiga is a Colombia-based marketing enterprise. Ruta Amiga has contracted with Ipsidy to use its Digital Issuance Platform to power Ruta Amiga's launch of a nationwide, multi-level marketing and rewards program involving several of the top consumer brands in Colombia.

Mr. Philip Beck, Ipsidy’s Chairman and Chief Executive Officer, said, "Ipsidy is pleased to partner with Ruta Amiga as it launches its new and exciting rewards program throughout Colombia. This project will further our goal of delivering solutions that allow our clients to build and manage trusted mobile ecosystems to grow their businesses in new ways."

Ipsidy, Inc. (IDTY), closed Friday's trading session at $0.1345, up 4.29%, on 113,500 volume with 10 trades. The average volume for the last 3 months is 166,409 and the stock's 52-week low/high is $0.075/$0.365.

chart

Alacer Gold Corp. (ALIAF)

Silverstocker, Gold Stock Data, Northern Miner, 4-Traders, Investopedia, OTC Markets, MarketWatch, InvestorPlace, TradingView, Investing, The Street, Mining Feeds, Penny Stock Tweets, and Information Vine reported previously on Alacer Gold Corp. (ALIAF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Alacer Gold Corp. is a foremost intermediate gold mining company based in Denver, Colorado. The Company has an 80 percent interest in the world-class Çöpler Gold Mine in Turkey operated by Anagold Madencilik Sanayi ve Ticaret A.S. The remaining 20 percent is owned by Lidya Madencilik Sanayi ve Ticaret A.S.  Alacer Gold is pursuing initiatives to enhance value beyond the present mine plan. Alacer Gold lists on the OTC Markets.

The Company’s main emphasis is to take advantage of its cornerstone Çöpler Mine and strong balance sheet to maximize portfolio value, maximize free cash flow, as well as minimize project risk. The Çöpler Mine is located in east-central Turkey in the Erzincan Province.

Çöpler has considerable Probable Reserves of 4 million recoverable ounces and Measured and Indicated Resources of 6 million ounces of contained gold. These provide the basis for Çöpler’s 20-year mine life. At present, the Mine is an open-pit, heap-leach operation producing low-cost gold from oxide ore. Over the life of the current heap-leach project, roughly 76 percent of the gold contained in the oxide ore is expected to be recovered.

In May of 2016, Alacer Gold’s Board of Directors approved full construction of the Sulfide Project at the Çöpler Gold Mine. The Çöpler orebody contains refractory sulfide ore. This requires a different processing solution than heap-leaching to extract the gold. The anticipation is that the Sulfide Project will deliver long-term growth with good financial returns and adds 20 years of production at the Çöpler Gold Mine. The Sulfide Project capital cost estimate has been reduced from $744 million to $673 million.

Yesterday, Alacer Gold announced additional positive drill results for the Ardich gold prospect. Further to the earlier announced 43 diamond core drill holes, a further 20 diamond core drill holes are being reported, with a majority intersecting mainly oxide gold mineralization. This include holes AR54 with 61.4m averaging 2.22 g/t gold from 5m depth, and AR52 with 57.7m averaging 3.84 g/t gold from 121.3m depth.

Alacer Gold Corp. (ALIAF), closed Friday's trading session at $1.66, up 0.61%, on 1,983 volume with 4 trades. The average volume for the last 3 months is 25,416 and the stock's 52-week low/high is $1.53/$2.28.

chart

HealthLynked Corp. (HLYK)

InvestorsHub and OTC Markets reported on HealthLynked Corp. (HLYK), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, HealthLynked Corp. focuses on improving healthcare services for patients and physicians. The Company’s technology cuts wait times with online scheduling of appointments and real-time appointments by local providers. Its technology also provides easy access to an individual’s and their family's updated medical records. HealthLynked is headquartered in Naples, Florida. The Company commenced trading on the OTC Markets Group’s OTCQB in May 2017.

HealthLynked centers on improving healthcare through connecting patients with their healthcare providers. The HealthLynked Network focuses on the efficient, secure exchange of medical information between patients and their healthcare providers.

The cloud-based HealthLynked Network lets patient's medical records move with them. This is so one’s medical records are not fragmented in manifold healthcare systems and/or EHR systems.

HealthLynked profile information safeguards that doctors don't prescribe potentially harmful medications in case a patient forgets to mention one or more present medications while talking to their doctor. Moreover, the HealthLynked Healthcare Summary page allows patients to keep their medical records updated. This helps physicians to be more productive and provide valid medical care.

Healthcare experts can easily be in touch with patients. They can provide their advice in case of emergencies via the Telemedicine Portal. The HealthLynked Healthcare Summary permits patients to maintain a complete medical profile in coordination with physicians. All information is systematically categorized. As a result, physicians have a total overview of patient health without them having to fill unnecessary paperwork.

This past September, HealthLynked announced it has created more than 880,000 HealthLynked Provider base profiles for every physician in the United States. The creation of the HealthLynked provider network is a vital step in allowing the Company’s patient members to search, geo-locate, and ultimately "Lynk" to any healthcare provider anywhere in the U.S.

Last month, HealthLynked announced its Q3 2017 financial results. It reported revenue of $480,723, and an operating loss of $512,153, which included roughly $135,500 of legal, accounting and other expenses related to the Company’s continuing public filings and investor relations cost and about $158,500 of incremental salary, benefits and other costs related to investment in initial sales and marketing efforts, and software development of the HealthLynked Network.

This was offset by a decrease in Naples Women’s Center’s general and administrative expenses of roughly $45,000, versus Q3 of 2016. The results compare with revenue of $516,798 and an operating loss of $482,570 in Q2 of 2016.

HealthLynked Corp. (HLYK), closed Friday's trading session at $0.24, even for the day, on 127,028 volume with 39 trades. The average volume for the last 3 months is 167,237 and the stock's 52-week low/high is $0.029/$0.65.

chart

Mobetize Corp. (MPAY)

Stockrow, Penny Stock Hub, Marketwired, MarketWatch, Investing Online, YCharts, GuruFocus, SmallCapVoice, Stockhouse, Street Insider, InvestorsHub, Market Screener, Capital Cube, Wallet Investor, Investors Hangout, Simply Wall St, and StockInvest.us reported earlier on Mobetize Corp. (MPAY), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Mobetize Corp. is a provider of mobile financial services (MFS) technology for the multi-billion-dollar Business to Business (B2B) segment of the Fintech as a Service (FaaS) sector. The Company has developed a global B2B Fintech as a Service (FaaS) Supermarket. Mobetize has offices in Blaine, Washington; Reno, Nevada; and Vancouver, British Columbia. Mobetize lists on the OTC Markets Group’s OTCQB.

Mobetize digitizes bricks and mortar financial services to deliver mobile money services to leading telecommunications companies and financial institutions. The Mobetize technology helps the telecom and banking industries boost their revenues, reduce customer service costs, and increase loyalty to existing offerings.

The Company ensures end-to-end integration for services. This includes prepaid air-time top ups, data gifting, mobile lending, international money transfers, P2P transfers, Visa™/MasterCard™ programs and mobile bill payments. Mobetize seamlessly integrates and white labels its secure mobile money platform for its customers who subsequently offer the services to millions of users.

Concerning Mobetize for Telecom Operators, the Company has its smartBill, smartRemit, smartWallet, smartCharge, and smartF/X. The Company’s lending solutions include smartLoan and smartMortgage.

The Mobetize smartCard is a prepaid Visa or MasterCard debit card tied to a person’s smartWallet for online and retail point-of-sale (POS) purchases. The Company says that its Mobetize smartLoan is the fastest and most cost-effective route for financial institutions to deploy digitized consumer lending.

In October, Mobetize announced a partnership with Xpress Money in a FinTech collaboration founded on its smartRemit solution. smartRemit has been licensed by FICANEX® to launch its first-rate service SendGlobal™ with their member financial institutions. smartRemit is a proprietary white-label payments solution. It enables worldwide money transfer capabilities internationally.

smartRemit is totally integrated with the Xpress Money remittance processing network to provide convenient, efficient, scalable, and inexpensive international money transfers for senders and recipients using mobile devices. The design of smartRemit is to meet international compliance and security requirements drawing on Xpress Money’s considerable experience in global money remittance.

Mobetize Corp. (MPAY), closed Friday's trading session at $1.50, up 25.00%, on 150 volume with 2 trades. The average volume for the last 3 months is 17 and the stock's 52-week low/high is $1.20/$4.45.

chart

Smoke Cartel, Inc. (SMKC)

NetworkNewsWire, Investors Hangout, Dividend Investor, TradingView, Stockopedia, Stockwatch, The Street, Penny Stock Hub, Stock News Feed, Wallmine, OTC Markets, Stockhouse, Street Insider, 4-Traders, Wallet Investor and InvestorsHub reported earlier on Smoke Cartel, Inc. (SMKC), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Smoke Cartel, Inc. is a leading online retailer and wholesaler of glass water pipes, vaporizers, and other related accessories for the cannabis industry. The Company began operations in 2014 in the State of Georgia. It was formerly known as Lemont, Inc. It changed its name to Smoke Cartel, Inc. in August 2017. The Company is based in Savannah, Georgia and lists on the OTC Markets.

Smoke Cartel operates in varied verticals within the online headshop industry. This consists of, but is not limited to, the sales of consumer products through online retail, sales of wholesale products to other retailers, the design and manufacturing of branded products, and shipping and fulfillment services. Its retail division has greater than 90,000 customers in 44 countries.

The Company previously acquired and undertook the integration of UPC Distribution into Glassheads Distribution, the wholesale division of Smoke Cartel. Furthermore, Smoke Cartel acquired and integrated Early Bird Distribution and all of its brands. Therefore, this expanded Smoke Cartel into new markets, such as the pet industry.

Smoke Cartel has covered a wide niche of glassware. The Company’s plan is to focus on non-glass products and accessories in the future to expand product selection and to reach new markets. Currently, Smoke Cartel has nine branded product lines to serve divers demographics in the smoking accessory market.

Last week, Smoke Cartel announced it launched retail and wholesale sales of the innovative Viosparc pipe lighter. Earlier in 2018, Smoke Cartel received allowance for the patent of the proprietary Viosparc. This is a fuel-free lighter designed specifically for pipe users.

Named the “Viosparc” for the violet color of its flame, the unique tool can ignite without the use of butane or propane and lights glass pieces at a unique, side angle for maximum efficiency. Furthermore, the Viosparc pipe lighter is rechargeable and reusable.

Yesterday, Smoke Cartel announced it completely integrated the assets purchased from its recent agreement with KushCo Holdings, Inc. On September 21, 2018, Smoke Cartel entered a strategic relationship with KushCo Holdings to take over sales of the cannabis packaging company’s glass and smoking accessories. This includes the Roll-Uh-Bowl brand and website. Smoke Cartel has now received all of the Roll-Uh-Bowl inventory and digital asset portfolio for RollUhBowl.com.

Smoke Cartel, Inc. (SMKC), closed Friday's trading session at $1.73, even for the day, on 45 volume with 1 trade. The average volume for the last 3 months is 7,355 and the stock's 52-week low/high is $0.99/$6.25.

chart

The QualityStocks Company Corner

Pressure BioSciences Inc. (PBIO)

The QualityStocks Daily Newsletter would like to spotlight Pressure BioSciences Inc. (PBIO).

Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sciences industry, today announced that significant progress has been made in its development program for its proprietary Ultra Shear Technology ("UST") platform.

Pressure BioSciences Inc. (PBIO) develops, markets and sells proprietary laboratory instrumentation and associated consumables to the life sciences sample preparation market. Sample preparation refers to the wide range of activities that precede most forms of scientific analysis. It is often complex and time-consuming, yet a critical part of scientific research. The market for sample preparation products is currently estimated at $6 billion worldwide.

The Company’s product line can be used to exquisitely control the sample preparation process. It is based on a patented, enabling technology platform called pressure cycling technology (“PCT”). PCT uses alternating cycles of hydrostatic pressure between ambient (14.5 psi) and ultra-high levels (up to 100,000 psi) to safely and reproducibly control critical biological processes, such as the lysis (breakage) of cells, the digestion of proteins, and the inactivation of pathogens.

Pressure BioSciences’ product line is led by its newly released, next-generation Barocycler 2320EXTREME instrument. Named a finalist in the prestigious 2017 R&D Awards (also known as the “Oscars of Innovation”), the Barocycler 2320EXT is already being touted by some key opinion leaders as an essential element of the $1.8 billion U.S. “Cancer Moonshot” program. For example, Professor Phil Robinson, Co-head of the cancer research center of the Children’s Medical Research Institute (Sydney, Australia), said in a recent interview: “We are collecting the whole proteome on 70,000 tumor samples from all classes where complete clinical outcome is known. Due to its unique capabilities, the Barocycler 2320EXT has become a critical part of our program. It is the primary enabler of the high-throughput component of the project. Without this step, our project simply could not be done. In fact, the Barocycler 2320EXT works so well we have just purchased two more.”

Momentum is building when it comes to the potential for using the Company’s unique PCT technology platform. Leading scientists are intrigued by Pressure BioSciences’ approach, which among other attributes, revolutionizes the process of rupturing cells (lysis) for further study, yielding superior biomolecules for investigation. The Company’s technology transcends current methods of breaking open cells, which use chemicals, blades, metal beads, or other damaging and altering methods that can ultimately adversely affect the result for researchers. Pressure BioSciences’ PCT technology utilizes customized, controlled hydrostatic (water) pressure to rupture cells in a chamber, enabling exquisitely customized levels of pressure to optimally break open different types of cells at prescribed pressure levels—something never before accomplished in a commercial setting. Using this pioneering method, the result is a truer, more legitimate sample, which boosts the efficacy of research and the quality of results. The potential impact of this technology on scientific advancement is enormous, enabling research scientists to begin their studies with biological samples of unprecedented integrity, with the potential to improve research outcomes at the earliest, most critical step. PCT can additionally inactivate pathogens (e.g., viruses, bacteria) using hydrostatic pressure, making the samples safer to study—another innovation with astronomical potential for application in a variety of markets.

The Company’s high-pressure instruments for research purposes are marketed throughout the United States, Europe, China and Japan. To date, Pressure BioSciences has installed nearly 300 PCT Systems in over 165 leading academic, government, biotech and pharma laboratories around the world. Its primary applications are in biomarker discovery, forensics, agriculture and pathology. Over 100 scientific papers have been published on the advantages of the PCT platform, which is also being used in the specialized fields of drug discovery and design, bio-therapeutics characterization, soil and plant biology, vaccine development and histology.

Impressive as their biotech business is, there is more to the PBI story. Pressure BioSciences recently received two patents in China for its novel Ultra Shear Technology (UST), a process that has potential in a wide range of industrial applications, including extending the shelf life of some food products and making two insoluble liquids (like oil in water) soluble. Patents have also been filed in many other countries worldwide. UST is a novel technique based on the use of intense shear forces generated from ultra-high-pressure valve discharge.

This important technology has the potential to play a significant role in a number of commercially important areas through its ability to create high-quality, stable nanoemulsions. Scientific studies indicate that improved absorption, higher bioavailability, greater stability, lower surfactant levels and other advantages can be achieved with nanoemulsions – all hugely important factors in the fields of nutraceuticals, cosmetics, pharmaceuticals, and in various medical products. There is an enormous opportunity in the cannabis market, since the technology can potentially reduce oil droplets containing cannabidiol (CBD) to nanoparticles, after which they can be safely suspended in a stable water solution—something many companies have endeavored to achieve without success. Researchers looking for a way to increase the bioavailability of cannabinoids in the body will find this technology a game changer.

The Company’s UST technology also has possibilities in the production of clean label foods, which are currently processed using several innovative methods, including high-pressure treatments (such as Starbucks’ Evolution line of juices). In 2015, the worldwide market for high-pressure processed (HPP) food was estimated at U.S. $10 billion. UST uses ultra-high pressures and certain valves to generate intense shear forces under controlled temperature conditions to produce nanoemulsions, and which also significantly reduces food-borne pathogens. Pressure BioSciences’ initial focus with this technology will be to evaluate UST for the production of high-quality dairy products and beverages.

Pressure BioSciences Inc. (PBIO), closed the day's trading session at $3.65, up 15.57%, on 7,780 volume with 31 trades. The average volume for the last 3 months is 2,769 and the stock's 52-week low/high is $2.59/$5.00.

Recent News

chart

Earth Science Tech, Inc. (ETST)

The QualityStocks Daily Newsletter would like to spotlight Earth Science Tech, Inc. (ETST).

Earth Science Tech, Inc. (OTCQB: ETST) is a biotech company developing and marketing health-oriented CBD products and continually expanding its product line to positively change individual lives. The company is doing this through the creation of products like its Hygee medical devices, a CBD beverage and KannaBidoiD products.

Earth Science Tech, Inc. (ETST) is an innovative biotechnology company operating in the fields of hemp cannabinoid (CBD), nutraceutical, pharmaceutical and medical device research and development. Earth Science Tech offers the highest purity and quality, full-spectrum, high-grade hemp CBD (cannabidiol) oil on the market. Made using the supercritical CO2 liquid extraction process, the company’s CBD oil is 100 percent natural and organic. Earth Science Tech has partnered with the University of Central Oklahoma and DV Biologics Laboratory to conduct research and development projects that scientifically support and advance the healthcare benefits of its high-grade hemp CBD oil.

Earth Science Tech Inc. currently has three wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors. These subsidiaries include:

  • Earth Science Pharma, Inc., which is committed to development of low cost, noninvasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. Earth Science Pharmaceutical CEO and chief science officer Michel Aubé is leading the company’s research and development efforts. The company’s first medical device, MSN-2, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. Earth Science Pharma is working to develop and bring to market medical devices and vaccines that meet the specific needs of women.
  • Cannabis Therapeutics, Inc. (“CTI”), which is poised to take a leadership role in the development of new, leading-edge, cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds a provisional application patent for a CBD product that is focused on developing treatments for breast and ovarian cancers.
  • KannaBidioiD (“KBD”) provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused edibles and vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy.

Earth Science Tech celebrated a significant, developmental year during 2017 by sharing its achievements in a condensed end-of-year report. Among the report’s highlights are the implementation of a development plan for the coming three years, which includes expanding into Canada and opening new manufacturing and shipping facilities. Of particular interest is the acquisition of Canna Inno Laboratories Inc., a company headquartered in Montreal, Quebec, Canada, which gives Earth Science Tech access to Canadian government grants offered to innovators in the pharmaceutical industry. ETST has also launched development of proprietary prophylactic therapies utilizing cannabidiol (CBD) to treat various forms of breast cancer.

In October 2017, ETST announced it is cooperating with the Clinique SIDA Amité (AIDS Friendship Clinic) for a mini-clinical trial, the last trial needed before the MSN-2 device, designed for the detection of STIs, enters molecular diagnostic trials. And in November 2017, the company began pre-launch human trials on a new CBD formula to fight against the U.S. opioid epidemic. The new formula, expected to decrease cravings and the negative effects of withdrawal in addicts, is based on industrial hemp CBD mixed with a known natural ingredient proven to help increase dopamine levels. ETST’s medical devices will first be launched in Vietnam, Djibouti and Morocco while the company awaits regulatory permission to enter the North American market.

The company expects to up-list to the OTCQB in early 2018, which management believes will attract well-funded institutional investors and pave the way to becoming the next billion-dollar-in-capitalization company on the OTC markets. Other highlights include completion of the company’s Scientific Advisory Council with a team of recognized scientists, the launching of several CBD-infused edible products and entry into the medical devices market through collaborative partnerships.

Earth Science Tech has signed a collaborate agreement with Laboratories BNK Canada, a private laboratory that will conduct the clinical studies necessary for MSN-2 medical device-related services to meet regulatory requirements. ETST has confirmed the MSN-2 device’s ability to detect chlamydia, and is working to validate similar results for gonorrhea, both highly infectious diseases that often have permanent consequences for patients. ETST will also add testing for trichomoniasis and a complete body fluid panel to detect the different serotypes of the human papillomavirus (HPV) that causes cervical cancer. These additions will help the company create sales opportunities in the global market for diagnostic testing of STDs that Transparency Market Research has indicated will grow to $108 billion by 2019.

Cannabis Therapeutics is in the development stage of two cannabinoid-based pharmaceutical drugs and three cannabinoid-based nutraceutical products targeting a variety of ailments such as anxiety, depression, triple negative breast cancer, and fatty liver disease, among others. Research into the benefits of the non-psychoactive cannabinoid molecules found in the cannabis plant is supported by ETST’s International Application for Provisional Patent titled “Cannabidiol Compositions Including Mixtures and Uses Thereof,” which was filed on October 8, 2015. Cannabis Thera’s R&D efforts are concentrated on developing CBD-based drugs and nutraceutical products and in working to integrate the CBD molecule with existing generic drug molecules to create more efficient medications with fewer and less severe side effects. A report in Hemp Business Journal predicts the CBD consumer market will grow to $2.1 billion by 2020, while other industry experts expect an increase to almost $3 billion by 2021. A recent report by Statista projects the U.S. consumer market for cannabinoid-based pharmaceuticals could reach $50 billion by the year 2029.

The management team at Earth Science Tech brings decades of invaluable experience to the nutraceutical, dietary supplement field as well as the life sciences sectors. Nickolas S. Tabraue, who serves as the president, director and chief operating officer, is an industry veteran with extensive knowledge of supplements, retail management, customer service and sales expertise. He is joined by CEO and CSO Dr. Michel Aubé, a microbiologist whose scientific research in sexually transmitted infections, cancer and stem cell biology has been widely published in several prestigious medical journals. Sergio Castillo, chief marketing officer, and Gabriel Aviles, chief sales officer, bring a wealth of marketing and sales experience to Earth Science Tech, which is complemented by Issa El-Cheikh, Ph.D., and his 25 years in the international finance, accounting, planning and execution of large scale transactions in the public and private sectors.

Earth Science Tech’s products include CBD, a natural constituent of hemp oil derived from hemp stalk and seed. EST offers CBD in the form of vitamins, minerals, herbs, botanicals, personal care products, homeopathies, functional foods and other products delivered in such forms as capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders and whole herbs. Earth Science products can be found at retail stores throughout the United States and are available for purchase through the internet.

Earth Science Tech, Inc. (ETST), closed the day's trading session at $1.02, up 6.25%, on 14,076 volume with 21 trades. The average volume for the last 3 months is 114,443 and the stock's 52-week low/high is $0.421/$2.45.

Recent News

chart

Plus Products Inc. (CSE: PLUS)

The QualityStocks Daily Newsletter would like to spotlight Plus Products Inc. (CSE: PLUS).

Plus Products Inc. (CSE: PLUS) (the “Company” or “PLUS”) today announced Cranberry Shortbread cannabis-infused gummies, its latest special edition, will be in stores for the 2018 Holiday season.  A perfect gift for everyone from the novice to the highly experienced cannabis user, PLUS Cranberry Shortbread gummies are dosable, discrete, and delicious.

Plus Products Inc. (CSE: PLUS) is a branded cannabis-infused products manufacturer of edibles created to support a healthy and active lifestyle. Headquartered in San Mateo, California, PLUS™ concentrates on producing edibles using extracts to ensure compliant, dosable and delicious products that provide a consistent cannabis experience.

First introduced to the market in 2015 to rave reviews, PLUS™ is now one of the top best-selling edible brands in California. PLUS™ operates through a wholly owned subsidiary, Carberry, and has four cannabis-infused gummy candy SKUs (in addition to limited edition SKUs), that are currently sold in over 200 licensed dispensaries and delivery services. All products under the PLUS™ brand are produced in the company’s 12,000-square-foot food-safe cannabis manufacturing facility in Adelanto, California.

PLUS Products shares are currently listed on the Canadian Securities Exchange. PLUS™ raised CAD$20 million through the offering, for which the lead underwriters were PI Financial and Canaccord Genuity. The company intends to use a portion of the IPO proceeds to fund rapid product capacity expansion, factory automation, working capital and new product development.

Operating in the largest adult-use recreational market in the U.S., PLUS Products holds a temporary manufacturing license in California and was one of the first brands to bring fully compliant products to the legal market. California legalized adult use recreational sales on Jan. 1, 2018, and industry analysts expect edible sales there will continue to amass enviable revenues. According to BDS Analytics, edibles made up 18 percent of marijuana retail sales in February 2018 across licensed retailers in California, with PLUS™ products ranking in the Top 10 of edible brands by retail dollar sales.

During the first half of 2018, PLUS Products generated US$2.45 million in sales, a marked improvement over 2017’s US$1.07 million in sales. The company’s established cannabis products are not only compliant with state laws, they are proving to be extremely popular with consumers. Among the PLUS™ product brands are:

  • Blackberry & Lemon RESTORE, an infusion of carefully dosed cannabis with a 9:1 THC to CBD per gummy.
  • Sour Watermelon UPLIFT, a low-calorie gummy crafted from carefully dosed cannabis with an infusion of 5mg THC per gummy.
  • Pineapple & Coconut CBD RELIEF, a tropical flavor gummy made from pure cannabis-derived CBD that is low-calorie, gluten-free and made with kosher ingredients.
  • Sour Blueberry CREATE, a low-calorie gummy infused with hybrid flower containing 5 mg THC.
  • Limited Edition Rose & Vanilla, available at select locations during Winter 2018, these gummies are crafted with 60 mg THC/30 mg CBD per tin.
  • Limited Edition RAINBOW SORBET gummies was created to celebrate Pride during Spring 2018 with a portion of each purchase donated to The Trevor Project, a confidential suicide hotline for LGBT youth.

“We are extremely proud of the products PLUS has brought to market,” remarked Jake Heimark, CEO and cofounder in a statement. “We’ve quickly grown into one of the leading edible brands in California. With the proceeds of this round, we will continue to further our mission: to make cannabis safe and approachable for all types of consumers.”

The PLUS™ team believes that everyone deserves access to consistent, dosable and delicious cannabis products and strives to make that happen. Producing the best infused products at scale requires thoughtful collaboration among experts in many fields. At PLUS™, our team is comprised of Chefs, Chemists, Food Manufacturing Experts, Engineers, Machinists, Visionaries, Creatives, Strategists and others.

Plus Products Inc. (PLUS), closed the day's trading session at $7.08, up 4.12%, on 289,151 volume with 245 trades. The average volume for the last 3 months is 376,698 and the stock's 52-week low/high is $3.51/$7.25.

Recent News

chart

Net Element (NASDAQ: NETE)

The QualityStocks Daily Newsletter would like to spotlight Net Element (NETE).

Net Element (NASDAQ: NETE), a global technology and value-added solutions group, recently announced the launch of Aptito, its complete Point-of-Sale (“POS”) solution on PoyntSmart Payment Terminal. To view the full press release, visit: http://nnw.fm/3mICv. Also today, CannabisNewsWire released a report highlighting the company examining how, over the coming months and years, more and more U.S. cannabis companies are likely to move north in order to list on stock exchanges in Canada. Many short term and long-term interests are driving this move.

Net Element (NETE), is a global financial technology and value-added solutions group that supports electronic payments acceptance in an omni-channel environment spanning across point-of-sale, e-commerce, and mobile devices. Net Element operates a payments-as-a-service transactional model and value-added services platform for small to medium enterprises in the U.S. and selected emerging markets. Internationally, Net Element’s strategy is to leverage its omni-channel platform to deliver flexible offerings to emerging markets with diverse banking, regulatory and demographic conditions. Net Element was ranked as one of the fastest growing companies in North America on Deloitte’s 2017 Technology Fast 500 ™ and South Florida Business Journal’s 2016 fastest growing technology companies.

Net Element believes the future of global commerce is being revolutionized as consumers quickly migrate toward omni-channel shopping utilizing mobile devices, desktop, and online services. Net Element’s all-in-one payment solutions support and unify a whole range of applications through a single, robust platform, allowing global onboarding and support for multiple payment methods.

With an eye on emerging markets, Net Element is pursuing growth opportunities and footholds in a number of industries. The company’s most recent application of its technology is to the cannabis industry, which is paced to hit $591 million and could increase 40 times in the next four years. This rampant growth also creates heightened need for smooth transactions between merchants and consumers. Payment processing and compliance for the cannabis industry has become increasingly complex, and Net Element’s Unified Payments subsidiary is addressing the challenges by offering a compliant, seamlessly integrated payment solution that makes it simple to transact.

Net Element has also launched a blockchain-focused business unit that will develop and deploy blockchain technology-based solutions. Net Element expects the new division to create a decentralized crypto-based ecosystem that will act as a framework for an unlimited number of value-added services, connecting merchants and consumers in a seamless, economically efficient transaction. This new business unit intends to also identify and invest in unique projects that decentralize and disrupt the payment processing industry by combining blockchain technology and real-world applications with talented development teams, strong fundamentals and addressable markets large in size.

“We believe that we’re at the dawn of a new evolution where additional digital payment methods are being introduced,” Net Element CEO Oleg Firer, says. “Introduction of our division focused on blockchain as part of the NASDAQ-listed entity will add transparency and compliance assurance to our investors as well as provide access to deploy value-added services to over 20 million electronic commerce clients that are currently part of Net Element’s growing network.”

Net Element clients are treated to customized solutions that provide the flexibility needed to keep up with customers. Among the services offered are mobile payment apps that accept payments anywhere, anytime; cloud-based solutions built to increase productivity and enhance revenue for clients and partners; marketing solutions that turn lookers into buyers; and business analytics that make it easy for clients to monitor business metrics, engage with customers and compare the competition. Its multi-channel platform combines e-commerce, offline, point-of-sale, comprehensive back office tools, mobile point-of-sale, credit scoring and customer interaction in one powerful platform-as-a-service technology.

Net Element owns and operates a global mobile payments and transactional processing provider, TOT Group, Inc., with the following subsidiaries:

  • Unified Payments – An award-winning, customized mobile billing and payments solution, recognized by Inc. Magazine as the No. 1 Fastest Growing Company in America in 2012.
  • Digital Provider – A leading provider of SMS messaging and mobile billing solutions.
  • Aptito – A next-generation, all-in-one, cloud-based restaurant management and point-of-sale payments platform using wireless technology.
  • Payonline – A fully integrated, processor agnostic electronic commerce platform.

Net Element is ranked No. 418 on Deloitte’s 2017 Technology Fast 500™ list of North America’s 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies. Net Element grew 190 percent. The company’s chief executive officer, Oleg Firer, credits the company’s progression to organic growth in its North America Transactions Segment, specifically the success of its Unified Payments brand, which focuses on value-added payment acceptance solutions for small to medium enterprises in the United States.

“The Deloitte 2017 North America Technology Fast 500 winners underscore the impact of technological innovation and world class customer service in driving growth, in a fiercely competitive environment,” said Sandra Shirai, vice chairman, Deloitte Consulting LLP and U.S. technology, media and telecommunications leader. “These companies are on the cutting edge, and are transforming the way we do business.”

Net Element’s suite of application performing interfaces (APIs) and connectors power commerce for businesses of all sizes through multi-channel platforms, all-in-one digital solutions, and end-to-end encryption of cardholder data utilizing tamper resistant hardware that ensures integrity and simplifies security.

Net Element’s corporate team is led by director and CEO Oleg Firer, who is responsible for the overall vision, strategy and execution of the company’s mission of powering global commerce. He is joined by CFO Jeffrey Ginsburg, CPA, and Steven Wolberg, who is the company’s chief legal officer and secretary. Each corporate officer brings a unique blend of leadership, vision, experience and creative energy to the company.

From mobile payments and value-added transactional innovations such as Digital Provider and Aptito to e-commerce and retail payment transaction processing brands like Payonline and United Payments, Net Element is transforming the online and mobile experience.

Net Element (NETE), closed the day's trading session at $6.13, up 3.90%, on 80,732 volume with 481 trades. The average volume for the last 3 months is 286,835 and the stock's 52-week low/high is $3.50/$33.51.

Recent News

chart

Sugarmade, Inc. (SGMD)

The QualityStocks Daily Newsletter would like to spotlight Sugarmade, Inc. (SGMD).

Sugarmade, Inc. (OTCQB: SGMD) is a product and brand marketing company that targets brands with disruptive potential and invests in them. Currently, the company has made a commitment to invest in Hempistry Inc. to the tune of $1 million. This investment will boost Hempistry’s efforts to produce ultra-high CBD-content hemp that is grown in Kentucky.

Sugarmade, Inc. (SGMD) one of the largest publicly traded hydroponics supply companies moving into the industrial hemp space, is a product and brand marketing company investing in products and brands with disruptive potential. Sugarmade’s brands include: ZenHydro.com; CarryOutSupplies.com; and BudLife. Headquartered in Monrovia, California, a city within Los Angeles county, Sugarmade has various business operations in diverse marketplaces including packaging and paper goods for various industries, agricultural supplies.

Sugarmade has expanded into the European hydroponics supply market with a growing base of orders taken through Amazon UK. Over the past few financial quarters, Sugarmade has seen revenue growth patterns expand geographically. As recently as mid-2017, the majority of hydroponic-related revenue growth was seen from California and other West Coast marketplaces, however growth is becoming more geographically dispersed among U.S. states where legalization has eased restriction. This movement into the United Kingdom further expands the base of geographic growth areas for Sugarmade.

Sugarmade recently launched a new corporate initiative in the booming industrial hemp and CBD, committing up to $1 million in capital over the next 12 months to invest in Hempistry, Inc., a privately held Nevada corporation. Hempistry has begun planting an ultra-high cannabidiol (CBD) industrial hemp strain on a land option it holds on 23,000 acres of prime Kentucky farmland. The strain of industrial hemp being grown by Hempistry is ultra-rich in CBD but contains less than 0.3 percent of THC, the psychoactive ingredient found in cannabis. The U.S. hemp industry is expected to produce well over $1 billion in revenues in 2018, with a compound annual growth rate of 14 percent through 2022, according to the Hemp Business Journal.

Demand for industrial hemp and products derived from hemp is soaring, with no let-up in sight, which the company sees as a “tremendous opportunity to become a supplier to this fast-growing sector,” said Chairman and CEO Jimmy Chan, who is also an advisor and minority shareholder of Hempistry.

Sugarmade’s investment into the market for high-CBD hemp is expected to be highly accretive for common shareholders in two ways. First, Sugarmade’s investment will be in the form of common shares in Hempistry allowing Sugarmade common shareholders to possibly benefit from any future initial public offering of Hempistry. Second, Sugarmade is expected to sign a supply agreement with Hempistry for cultivation supplies, which would be additive to corporate revenues.

Sugarmade has also completed a master market agreement with industry leader BizRight Hydroponics, Inc., a leading marketer and manufacturer of cannabis and hydroponic growth supplies, which offers a range of hydroponics-related products including: HPS grow lights, electronic ballasts, HPS bulbs, nutrient mixes, environmental control products, pH measurement and calibration solutions and storage products. BizRight operates the ZenHydro.com website and other e-commerce properties and sells various products to distributors and retailers. BizRight is expected to produce in excess of $30 million in revenues during 2017, with substantial growth expected for 2018.

Sugarmade division CarryOutSupplies.com, the leader in paper and plastic take-out supplies, serves nationwide customers by offering a wide array of high quality products that are cost-efficient, custom-made and delivered on time. This business unit currently serves 2,000 quick service restaurants, garnering from 30-40 percent of the market share. Sugarmade plans to expand operations via the addition of market share and the introduction of new product offerings.

Management

CEO Jimmy Chan is an experienced business executive instrumental in growing multiple business operations with a strong expertise in international trade and banking, and international manufacturing and importation. He is also the founder of CarryOutSupplies.com, a company that revolutionized the custom-printed paper supplies subsector of the quick service restaurant industry, which merged with Sugarmade in 2014.

Arman Tabatabaei serves as operations consultant, providing high-level, day-to-day strategic guidance and tactical operational supervision for all aspects of the corporation’s business. He is an expert at data collection and analysis relative to resource management, risk forecasting and profit and loss management.

Sugarmade specializes in growing and acquiring innovative brands to maximize value for company employees, shareholders and other stakeholders. Sugarmade believes its future is very bright as the company expands operations within the cultivation sector and rapidly increases its revenue base.

Sugarmade, Inc. (SGMD), closed the day's trading session at $0.111, up 3.74%, on 532,250 volume with 103 trades. The average volume for the last 3 months is 2,543,576 and the stock's 52-week low/high is $0.05/$0.43.

Recent News

chart

TMSR Holding Company (NASDAQ: TMSR)

The QualityStocks Daily Newsletter would like to spotlight TMSR Holding Company (TMSR).

TMSR Holding Company (NASDAQ: TMSR) is a developer and provider of advanced industrial and mining waste management solutions that offers various industries a way to transform waste into useful materials. To view the full article, visit: http://nnw.fm/Fjf23.

TMSR Holding Company (NASDAQ: TMSR), together with its subsidiaries, is a recognized leader in the research, development, production and sale of solid waste recycling systems and zero emissions process systems, for the industrial and mining sectors in the People’s Republic of China. The company operates through its wholly owned business divisions: Shengrong Environmental and Wuhan HOST Coating Materials.

TMSR’s Shengrong subsidiary designs, builds, sells and services customized solid waste recycling systems and equipment for some of the largest industries in China. The company provides customers full-service, tailor-made systems from conceptual design to planning, production, modernization, optimization, assembly, start-up, conversions, disassembly, maintenance and servicing of components to complete zero emissions solid waste recycling and process systems.

Utilizing what management believed to be the world’s most advanced technologies of physical magnetic industrial solid waste recovery, Shengrong can process a variety of industrial solid waste materials and is able to extract valuable metal byproducts from the waste without generating any chemical pollution. Shengrong’s patented equipment can process aluminum slag, copper mine tailings, iron mine tailings, red mud manganese tailings, and molybdenum tailings among many others. Unlike traditional chemical-based recovery methods, the company extracts resalable metals from the waste without generating any pollution. The residues are processed to manufacture high-quality construction materials, turning polluted solid waste into valuable industrial materials with zero discharge.

Industrial solid waste recycling and heavy metal removal are significant worldwide technical, financial and environmental issues. Through Shengrong, TMSR is addressing this profound unmet market need by delivering end users a clean alternative to traditional waste disposal. The company intends to leverage these serious unmet needs, expand its patented industrial waste recycling systems to broad international markets, and provide global industrial and mining businesses cost-effective, patented green technology platforms that create new-found revenue streams for end users.

Through Shengrong, TMSR owns two U.S. patents and five patents granted by the Peoples Republic of China, including four invention patents and two utility model patents. The company’s research and development efforts have achieved technological advancements that allow end users to eliminate pollutant discharge as well as generate new revenue streams by selling valuable byproducts extracted from industrial waste.

TMSR subsidiary, Wuhan HOST Coating Materials, is the largest manufacturer of inorganic Zinc-rich resin and one-component epoxy Zinc-rich resin in China. Established in 2010, Wuhan HOST is a leader in the research and development, production and sale of Zinc-rich coating materials throughout the PRC and has a broad customer base that includes some of the foremost enterprises in major industries such as electricity, metallurgy, machinery, chemicals, bridge and shipping. TMSR completed the acquisition of 100% equity interest in Wuhan HOST Coating Materials on May 1, 2018.

Notably, TMSR first went public as JM Global Holding Company, a Special Purpose Acquisition Company (SPAC) formed to effect a merger, asset acquisition or other business combination that had exceptional growth potential. After reviewing over 50 potential targets and completing due diligence and third party analysis, JM Global identified China Sunlong Environmental Technology Inc. and its wholly owned subsidiaries as the acquisition target. Upon closing the business combination, the company was re-named TMSR Holding Company Ltd.

Demand for TMSR’s products is expected to grow significantly due to Chinese policies that encourage mining and manufacturing companies to adopt “green” technology. Approximately 3 billion tons of industrial solid waste were generated annually in China between 2011 through 2015.  Currently, 95% of industrial solid waste in China is stored in special facilities and sites; however, the cost of storage, disposal and incineration of industrial solid wastes is high. TMSR is focused on exploiting this unmet need, providing end users in the solid waste recycling markets a clean alternative to traditional waste disposal, significantly reducing solid waste discharge into the environment and enabling end users to extract value from industrial waste materials.

TMSR Holding Company (TMSR), closed the day's trading session at $2.76, even for the day, on 36 volume with 1 trade. The average volume for the last 3 months is 8,761 and the stock's 52-week low/high is $1.84/$10.322.

Recent News

chart

NUGL Inc. (NUGL)

The QualityStocks Daily Newsletter would like to spotlight NUGL Inc. (NUGL).

MoneyTV coverage has been initiated for NUGL, Inc. (OTCPINK: NUGL) and the company was featured on MoneyTV with Donald Baillargeon. Also today, CannabisNewsWire released a report highlighting the company examining how, over the coming months and years, more and more U.S. cannabis companies are likely to move north in order to list on stock exchanges in Canada. Many short term and long-term interests are driving this move.

NUGL Inc. (NUGL) is focused on leading the evolution in business relations, development and organic data in the cannabis industry with a distinct platform. In this effort, it has developed a leading-edge, first of its kind search app and online directory for the marijuana industry that provides a one-stop source and listings for dispensaries, strains, doctors, lawyers, service professionals, vape shops, hydro stores and brands.

Headquartered in Chino Hills, California, which is home to a projected $5 billion legal marijuana marketplace, NUGL is on track to become a major asset for the global cannabis industry and related services sectors. The company recently established a strategic partnership with Thinklogic and appointed CEO Chris Adams to NUGL’s growing board of directors. Thinklogic is a top-level software development company specializing in projects for start-ups to Fortune 500 companies.

“This strategic partnership puts NUGL in a distinguished class, adding a first-rate technical software expert like Chris gives NUGL a unique technological advantage,” said Brandon Vargas CEO of NUGL. “With the addition of Chris’s knowledge and expertise combined with Thinklogics’ experienced and skilled staff, NUGL will have the ability to evolve and build a strong infrastructure unmatched in the 420 industry.”

NUGL is nearing completion of its initial launch timeline, with plans to launch the app on both Android and iOS platforms within the next few weeks. NUGL’s live testing of its software includes enhanced reviews that detail up to 10 category ratings. Each of the category rankings allow users to leave comments and choose among a 5-star rating among all categories or as few as they wish. The software’s rating platform allows for customization and transparency for users while providing invaluable feedback to shops and professional services.

“This is a major feature that is critical to our community,” said Jeff Odle, NUGL’s CTO. “Enhanced ratings will be a definitive difference validating our organic listings and raising the standard for the industry. We want the users to know what they are getting before they step into a store or sign up for a service.”

Leadership Team

NUGL is growing its team of developers and launching new features on an ongoing basis. The company is ahead of an impressive timeline, which includes building blocks for scalability and massive growth.

“Everything we do is focused on user experience. Our philosophy is simple – make it fun and easy to use, with the purest and most unbiased results,” said Ryan Bartlette, NUGL CMO. “As the industry evolves and becomes more sophisticated, NUGL will adapt and build the best marketing technology for the cannabis-related companies. We have gotten in on the ground level and know the pulse of the industry.”

NUGL CEO Brandon Vargas is a founding member of G6 Management, a full-service consulting firm advising cannabis professionals in all aspects of business. With over 10 years’ experience in the cannabis space, he has worked on dispensary, cultivation and infusion entity formation, licensing, real estate acquisitions, construction and build out, marketing, policy and procedures, compliance, staffing, and capital raises. Vargas has an extensive background working with various medical marijuana companies on investment and in developing greenhouse and commercial cultivation, distillate for vapes cartridges, CBD oils and infusions.

CMO Ryan Bartlette is co-founder and CMO of 23Forty LLC and Boxy. He has expertly positioned and branded many companies while bringing them to market and is a sought out graphic artist, front-end developer, photographer, and visual artist with experience in the entertainment and technology industry.

Jeff Odle, NUGL CTO, is a successful senior software architect has a long and distinguished career developing some of the most innovative, cutting-edge platforms available. His unique and distinctive approach to creating the blueprint for advanced programming is industry leading and unprecedented. He is a top-level architect responsible for developing some of the most forward-­looking software for various industries.

NUGL’s board of directors includes John R. Armstrong, a founding partner of Horwitz + Armstrong, a full service general business firm handling all aspects of litigation and business strategy and advice. Armstrong and his partner, Lawrence Hortwitz, have more than 10 years of experience in the cannabis space, representing cannabis professionals in all aspects of business including business formation, licensing, compliance with local and state regulations, real estate acquisitions, corporate mergers and acquisitions, financing, inclusive of capital raises and alternative financing, contracts, and all forms of dispute resolution.

Board member Hendrik Klein, founder of Da Vinci Asset Management, a privately-owned investment firm, serves as CEO and executive board member of Fritz Nols AG, a capital marketing consulting firm specializing in trading and asset management. Klein has received several industry awards including the Austrian Hedge Fund Award, the German Hedge Fund Award, and most recently was named the Global Best Performing Systematic Quantitative CTA. Klein and the Da Vinci team employ the latest quantitative data research and analysis in their innovative investment strategy.

NUGL Inc. (NUGL), closed the day's trading session at $2.00, up 0.50%, on 54,811 volume with 114 trades. The average volume for the last 3 months is 191,133 and the stock's 52-week low/high is $0.405/$2.64.

Recent News

chart

CytoDyn Inc. (CYDY)

The QualityStocks Daily Newsletter would like to spotlight CytoDyn Inc. (CYDY).

CytoDyn Inc. (OTCQB: CYDY) (the "company"), is a biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications. Nader Z. Pourhassan, Ph.D., President and CEO, talked with Stock Day's Everett Jolly.

CytoDyn Inc. (CYDY) is a biotechnology company focused on the clinical development and potential commercialization of a new class of HIV/AIDS therapeutics or viral-entry inhibitors intended to protect healthy cells from viral infection. The company’s pipeline includes its lead product, PRO 140 for multiple indications among which are human immunodeficiency virus (HIV), graft-versus-host disease (GvHD), colon cancer, and multiple sclerosis (MS), each in various stages of development. CytoDyn first approval is focused on HIV indications for two different HIV populations.

PRO 140 is a humanized monoclonal antibody directed at CCR5, a molecular portal that HIV uses to enter T-cells. PRO 140 works by blocking the predominant HIV (R5) subtype entry into T-cells by masking this required co-receptor, CCR5.

CytoDyn has completed one pivotal phase 3 clinical trials of PRO 140 use in combination with current drugs for population that has limited treatment options. PRO 140 is also currently in another phase 3 (investigative trial) for a second approval for another HIV population. HIV continues to be a major global public health issue. There is no cure for the disease that has claimed more than 35 million lives to date, according to the World Health Organization (“WHO”). In 2017, 940,000 people around the world died from HIV-related causes. There were approximately 36.9 million people living with HIV at the end of 2017 with 1.8 million people becoming newly infected during that same year. The WHO estimates there were 21.7 million people globally receiving antiretroviral therapy (“ART”) in 2017.

HIV targets the immune system and weakens the body’s defense systems against infections and some types of cancer. As the virus destroys and impairs the function of immune cells, infected individuals gradually become immunodeficient which results in increased susceptibility to a wide range of infections, cancers and other diseases that people with healthy immune systems can fight off. The most advanced stage of HIV infection is Acquired Immunodeficiency Syndrome (AIDS), which can take from 2 to 15 years to develop depending on the individual.

PRO 140 functions by blocking the HIV co-receptor CCR5, a molecular portal HIV uses to enter T-cells, thus preventing the HIV virus from entering the cell. CCR5 is a protein located on the surface of white blood cells that normally serves as a receptor for chemicals that attract immune cells to the site of inflammation. Clinical trials to date indicate PRO 140 does not interfere with these normal CCR5 functions. Results from phase 1 and phase 2 human clinical trials have shown PRO 140 significantly reduces viral burden in people infected with HIV. Importantly, in a recent phase 2b clinical trial, PRO 140 demonstrated it can allow a subset of R5 strain of HIV population to replace their current HIV regimen (Highly Active Antiretroviral Therapy or “HAART.”) by a simple sub-cutaneous self-injectable dose of PRO 140 which is administered once a week. Some of those patients have received PRO 140 as their only therapy for almost four years.

The PRO 140 antibody appears to be a powerful antiviral agent with hardly any side effects, toxicity. More than 500 patients have used PRO 140 in clinical trial and no resistance has ever been developed in any patients including patients in monotherapy of PRO 140 for almost four years.

PRO 140, which is taken as an easy-to-use, weekly, subcutaneous self-administered dose, has almost no side effects or toxicity with no report of any serious adverse event related to PRO 140 in more than 500 patients in eight different clinical trial.

As we indicated earlier patients given PRO 140 showed no drug resistance on monotherapy for some almost four years while 76% of HAART patients developed a resistance to some portion of the lifetime drug regimen. Patient compliance with HAART is also the main reason why only 35% of HIV patients in US reporting complete viral load (VL) suppression which is VL<50 cp/mL.

In addition to its research into the powerful potential of PRO 140 for use in HIV patients, CytoDyn is pursuing PRO 140 as a therapeutic anti-viral agent in other non-HIV indications that could benefit from PRO 140’s ability to block CCR5. These immunologic indications include new reactions to cancer, transplantation rejection, autoimmune diseases and chronic inflammation such as Multiple Sclerosis. The company sees the significant potential for multiple pipeline opportunities for PRO 140.

The U.S. Food and Drug Administration has designated PRO 140 as a “fast track” product for HIV and granted Orphan Drug Designation to it for the prevention of GvHD in transplant patients. CytoDyn has initiated its first clinical trial with PRO 140 in an immunological indication for GvHD in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who are undergoing bone marrow stem cell transplantation. The company is also investigating PRO 140 in animal models of cancer progression and autoimmunity with positive results and has published its animal study results in GvHD in peer-reviewed journal.

CytoDyn president and CEO Nader Z. Pourhassan, Ph.D. joined the company in 2008 and is credited for purchasing PRO 140 from Progenics in 2012 and has taken a new path to approval for the product. He is the co-inventor of monotherapy path for PRO 140. He has taken PRO 140 development from phase 2 to Completed successful phase 3 in about four years. He now has more than 10 years of drug development experience and has overseen the rapid clinical development of PRO 140 as a therapy for HIV into two phase 3 for two different indications. He also initiated PRO 140 first immunological indication in GvHD (currently in phase 2). He is also involved in preclinical and clinical development of PRO 140 in additional immunological indications.?Dr. Pourhassan, who has more than 20 years of business development experience, has led CytoDyn’s capital market activities since joining the company in 2008. He received his Bachelor of Science from Utah State University, Master of Science from Brigham Young University, and his Ph.D. in Mechanical Engineering from the University of Utah and is the author of three books.

CytoDyn Inc. (CYDY), closed the day's trading session at $0.575, up 1.77%, on 64,852 volume with 26 trades. The average volume for the last 3 months is 237,220 and the stock's 52-week low/high is $0.40/$0.836.

Recent News

chart

Lithium Chile Inc. (TSX.V: LITH) (OTC: LTMCF)

The QualityStocks Daily Newsletter would like to spotlight Lithium Chile Inc. (LTMCF).

Mineral explorer Lithium Chile (TSX.V: LITH) (OTCQB: LTMCF) is drilling for commercially productive sources of the soft metal in the lithium-rich brine fields of Chile. To view the full article, visit: http://nnw.fm/gN110.

Lithium Chile Inc. (TSX.V: LITH) (OTC: LTMCF), headquartered in Canada, is advancing one of the largest lithium-rich exploration portfolios in Chile consisting of more than 148,000 hectares covering sections of 13 salars or mineral salt flats and one laguna complex. The company’s wholly owned premier properties include 66 square kilometers on the Salar de Atacama, Chile’s largest mineral salt flat which hosts the world’s highest concentration of lithium brine production and is currently the source of about 35 percent of the world’s lithium production. Lithium Chile also owns a significant copper/gold/silver property portfolio consisting of 28,184 hectares over six different properties.

Lithium Chile’s portfolio in the heart of Chile’s lithium-rich salars includes Salar de Coipasa, Salar de Helados, Salar de Atacama, Salar de Turi Salar de Ollague and Salar de Talar. Surface and near surface salt and brine sampling programs on all properties has been completed. To date, samples of high-grade, near-surface lithium brines at each of these projects are showing excellent chemistry of lithium to potassium and lithium to magnesium ratios. Good chemistry is important as it reduces your overall cost of production. Recent geophysical surveys including T.E.M have been completed on 5 of 6 priority targets and data collected to date has been extremely encouraging.

Lithium Chile has identified multiple high-priority brine target areas at its Atacama and Ollague lithium project areas. These areas display the same geophysical characteristics as the lithium-rich aquifers at Salar de Atacama, home to the world’s largest and highest-grade lithium brine producers. Spanning an area of 1,200 square miles, Salar de Atacama is the world’s third largest salt flat behind Salinas Grandes in Argentina and El Salar de Uyuni in neighboring Bolivia. Exploration drilling and resource definition drilling for these target areas are planned for 2018.

“We are delighted with the discovery of such impressive drill target areas at Atacama and Ollague. The results also follow the recent discovery of a 60km2 target area at another of our top Chilean projects – Helados – where we hope to drill in the second quarter of 2018,” stated President and CEO Steve Cochrane. “We have an aggressive multi-project drill program planned for this year, which includes all three of these exciting projects and we look forward to sharing drill results as they come through.”

Global demand for lithium-ion batteries is expected to surpass US$53 billion by 2024 as governments around the world aggressively seek to ban gas-powered vehicles and major automakers invest billions in new technology and electric vehicles powered by lithium-ion batteries. Chile’s mining-friendly jurisdiction offers Lithium Chile a clear, streamlined permitting process that significantly lowers the cost of lithium production to around $1,800/ton as compared to Australia’s $5,000/ton.

Lithium Chile is led by an experienced team with strong Chilean connections. Cochrane’s 36 years of investment industry experience have primarily been focused on the mining sector. During this time, he raised more than US$500 million for a variety of small cap public companies in various businesses and industry sectors including mining.

Terry Walker, P.Geol., vice president of exploration and chief geologist, is a highly experienced geologist. He has spent over 25 years in Chile’s mining industry and is well connected throughout the sector. Walker is co-founder of GeoServicios Piedra Dorada, an exploration and development services company focused on Latin America. He is a Qualified Person for the North American and Australian stock exchanges.

Lithium Chile is well funded and driven by a top-tier team with more than 100 years of combined experience in financing, mining exploration and development in the natural resources sector.

Lithium Chile Inc. (LTMCF), closed the day's trading session at $0.47987, up 4.32%, on 59,193 volume with 21 trades. The average volume for the last 3 months is 50,445 and the stock's 52-week low/high is $0.4225/$0.97.

Recent News

chart

BriaCell Therapeutics Corp. (OTC: BCTXF) (TSX.V: BCT)

The QualityStocks Daily Newsletter would like to spotlight BriaCell Therapeutics Corp. (BCTXF).

BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) is developing the first personalized, off-the-shelf advanced breast cancer immunotherapy option using its proprietary targeted immunotherapy technology, company president and CEO Dr. Bill Williams said in a recent interview with Stock Day’s Everett Jolly (http://nnw.fm/B2Vwc).

BriaCell Therapeutics Corp. (OTC: BCTXF) (TSX.V: BCT), based in Berkeley, CA, and headquartered in Vancouver, British Columbia, is a clinical-stage biotechnology company focused on the development of targeted immunotherapy for advanced breast cancer.

BriaCell hopes to develop and market the first off-the-shelf personalized immunotherapy for the treatment of advanced breast cancer.

The results of two previous proof-of-concept clinical trials produced encouraging results in patients with advanced breast cancer. Most notably, one patient with breast cancer that had spread to other sites (metastatic cancer) responded to Bria-IMT™ with a substantial tumor shrinkage in multiple sites including the breast, the lung, soft tissues and even the brain. Similar observations have been confirmed more recently in additional patients, and BriaCell is developing BriaDX™ as a way to identify those patients most likely to respond.

BriaCell has recently completed recruitment of a Phase I/II study (NCT03066947) of Bria-IMT™, the Company’s lead product candidate, in advanced breast cancer patients showing an outstanding safety profile and excellent efficacy. BriaCell is currently enrolling advanced breast cancer patients in a combination therapy trial (NCT03328026) of Bria-IMT™ with Keytruda® (Keytruda® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.) or Yervoy® (Yervoy® is a registered trademark of Bristol-Myers Squibb Company). For further information on the Phase IIa clinical trials, please visit trial NCT03066947 and trial NCT03328026.

BriaCell’s pipeline also includes Bria-OTS™, the first off-the-shelf personalized immunotherapy for advanced breast cancer; and, a companion diagnostic product BriaDX™. By using BriaDX™ to identify and treat the patients who would most likely benefit from their immunotherapies, BriaCell expects to personalize the treatment for the patients, and bring hope to thousands of cancer patients who currently have few-to-no treatment options.

Breast Cancer Statistics

The National Cancer Institute estimates that more than 265,000 new cases of female breast cancer will be diagnosed in the U.S. during 2018, and that more than 40,000 women in the U.S. will die from the disease. Approximately 12 percent of women will be diagnosed with breast cancer at some point during their lifetime, based on 2013-2015 data.

Using its novel technology platform and strong R&D capabilities, BriaCell believes it has the opportunity to address this market, as well as have the opportunity to develop immunotherapy candidates for other cancer indications.

The global cancer immunotherapy market is expected to reach nearly USD$203 billion by 2025.

BriaCell Therapeutics Corp. (BCTXF), closed the day's trading session at $0.083, even for the day. The average volume for the last 3 months is 18,775 and the stock's 52-week low/high is $0.068/$0.1387.

Recent News

chart

ChineseInvestors.com (CIIX)

The QualityStocks Daily Newsletter would like to spotlight ChineseInvestors.com (CIIX).

ChineseInvestors.com, Inc. (OTCQB: CIIX) CEO Warren Wang unveiled two new TV commercials they are airing this week on MoneyTV with Donald Baillargeon. Also today, it was reported that CIIX’s core businesses of investor relations and subscriptions drove 70 percent of its 1Q19 revenues, the company reported. It also had 70 percent higher YOY sales for its first quarter (http://nnw.fm/bH36s).

Founded in 1999, ChineseInvestors.com (CIIX) has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.

Through its primary website, www.ChineseInvestors.com, CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services.

At the center of this initiative is the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. Using this strategy, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.

CIIX is also leveraging its financial expertise to enter into the burgeoning CBD industry, which within a few years has grown from a relatively invisible sector to a billowing market expected to reach $2.1 billion in consumer sales by 2020.

The increasing demand for CBD-based products is a catalyst for innovative business endeavors. To this accord, CIIX has established a three-year development plan to capitalize on the convergence of CBD and the nutrition and health products market in mainland China, where the benefits of CBD oil have not been widely recognized.

Under a wholesale agreement with a reputable CBD health brand, CIIX is launching the world’s first online CBD health products store published in the Chinese language. The site, www.ChineseCBDoil.com, caters to a growing number of Chinese people awakening to the numerous health benefits of CBD oil for treatment of a variety of conditions such as anxiety, stress, poor sleep, Alzheimer’s disease, and more. CIIX expects to launch this website at the end of January 2017, and plans to sell CBD-infused products via online and in-store.

In conjunction, CIIX’s cannabis-focused “Yelp”-style mobile app is in development as a platform for Chinese people to review and discuss various cannabis products. The app will be the first marijuana social media mobile app designed for Chinese-speaking customers worldwide.

ChineseInvestors.com (CIIX), closed the day's trading session at $0.635, even for the day, on 67,928 volume with 66 trades. The average volume for the last 3 months is 651,221 and the stock's 52-week low/high is $0.365/$1.58.

Recent News

chart

SinglePoint, Inc. (SING)

The QualityStocks Daily Newsletter would like to spotlight SinglePoint, Inc. (SING).

SinglePoint (OTCQB: SING) was a featured company on this week’s episode of MoneyTV with Donald Baillargeon. To view the full interview, visit: http://nnw.fm/cNdi4. To view the full press release, visit: http://nnw.fm/IKI9z.

SinglePoint, Inc. (SING) is a diversified holding company with operations in multiple industries and verticals including two high-performing market sectors: legal cannabis and cryptocurrencies. SinglePoint has grown from a full-service mobile technology provider to a recognizable brand with a diverse portfolio of undervalued subsidiaries with multiple revenue streams.

SinglePoint is researching opportunities where it can be an active participant by influencing the strategy and direction of high-potential companies whose verified assets offer attractive possibilities for shareholders. The company is guided by a visionary leadership team with extensive experience in technology, engineering, marketing and raising capital.

SinglePoint is bullish on the cannabis industry, bitcoin and blockchain technologies, which is evident in its recent acquisitions and joint-venture announcements. Recent SinglePoint key highlights include:

  • A joint venture with Smart Cannabis Corporation (OTC: SCNA) to license and market Smart Cannabis’ SMART APP. SMART APP enables cannabis growers to measure all aspects of cultivation, from soil nutrient levels to watering cycles and carbon dioxide content in the air. SMART APP will integrate SinglePoint’s bitcoin payment solution to enable growers to process safer and more secure transactions.
  • A joint venture with Global Payout (OTC: GOHE) will build on existing financial technology solutions developed by SinglePoint and Global Payout’s subsidiary MoneyTrac Technology, Inc., to fully optimize the delivery of mobile payment applications for domestic and international organizations.
  • A joint venture with AppSwarm (OTC: SWRM) to start development on a proprietary delivery application that will enable licensed cannabis delivery services and licensed dispensaries to safely make in-home cannabis deliveries.
  • Signed original “Shark Tank” member Kevin Harrington as company spokesman for an innovative, compatible virtual wallet to store any type of cryptocurrency. Harrington recently finished shooting a new national ad campaign featuring SinglePoint and the virtual wallet’s secure method of storing cryptocurrencies.
  • Entered into a letter of intent to acquire 100 percent of Bitcoin Beyond, a premier platform that enables merchants to accept bitcoin payments using existing web-enabled point-of-sale devices.
  • Through SING subsidiary, SingleSeed, the company will soon offer a proprietary cryptocurrency solution that links both cannabis merchants and consumers who seek to take advantage of bitcoin-powered transactions using debit and credit cards. In addition to making bitcoin-backed card purchases possible, the solution enables cannabis dispensaries to digitally track and manage their product inventories, performing tasks like uploading product data, photos and descriptions. The system deducts items automatically from a dispensary’s product listings when a purchase is made. While this fully KYC-AML compliant point-of-sale platform can be utilized for any other retail setting, it will fill a critical need in the underbanked cannabis industry as it continues to seek non-cash payment solutions outside of traditional banking circles.

SinglePoint CEO and founder Greg Lambrecht leads the company in its mission to capture opportunities through an aggressive expansion strategy across a broad range of assets. Lambrecht oversees all company operations including investor relations, leadership of the board of directors, and daily business activities. As the founder of PCI, a leading consumer product distribution company, Lambrecht negotiated agreements with the nation’s largest retail outlets and led PCI through a NASDAQ listed IPO, raising $10 million.

Eric Lofdahl, SinglePoint’s chief technology officer, has more than 20 years of experience in the technology sector including positions in software development, program management, complex system integration and engineering process definition. Prior to SinglePoint, Lofdahl worked at the Boeing Company where he led a team that successfully developed advanced wireless and satellite data products based on commercial technology for the U.S. Air Force.

SinglePoint President Wil Ralston is well known for his successful track record of building and maintaining great relationships with clients. Ralston graduated cum laude from the WP Carey School of Business at Arizona State University with a degree in Global Agribusiness and a specialization in Professional Golf Management. He is currently recognized by the Professional Golfers Association of America (PGA) as a Class A Professional.

SinglePoint, Inc. (SING), closed the day's trading session at $0.0256, off by 2.48%, on 2,407,737 volume with 104 trades. The average volume for the last 3 months is 4,400,156 and the stock's 52-week low/high is $0.0235/$0.133.

Recent News

chart

Medical Cannabis Payment Solutions (REFG)

The QualityStocks Daily Newsletter would like to spotlight Medical Cannabis Payment Solutions (REFG).

Medical Cannabis Payment Solutions (OTC: REFG) stand to gain if the predictions of two legislators that federal cannabis legalization bills will be passed in Congress in 2019 are correct. The Congressmen said at a session of the Cannabis Law Institute, hosted by The National Cannabis Bar Association, at George Washington University, that legislation to legalize cannabis nationally is anticipated next year no matter which party controls Congress (http://cnw.fm/L622f).

Medical Cannabis Payment Solutions (REFG), headquartered in Cheyenne, Wyoming, is a first-tier merchant processing cannabis industry pioneer, offering one of the first and only comprehensive card processing operations of its kind to serve the state-sanctioned medical marijuana industry. The company’s state of the art system, which also tracks sales and tax collection, and eliminates the need to deal in cash-only transactions.

Through its robust, closed-loop merchant processing system, the company’s unique “StateSourced” proprietary system enables authorized operation under FinCEN parameters and complies with all regulatory frameworks. StateSourced is tailored to deliver full-spectrum merchant processing services, providing the convenience of modern commercial card processing resources and making it the first operation of its kind geared to the legal cannabis industry.

StateSourced is not a prepaid or gift card, which is an important variable for merchants since standard banking institutions have not offered this form of payment processing to the legal cannabis industry. Federal law still considers marijuana illegal under the Controlled Substances Act, although 29 states and the District of Columbia have legalized the plant either for medicinal or recreational uses or both. This restriction has kept financial institutions at bay since most banks are federally insured and haven’t been inclined to venture into the nascent industry.

Medical Cannabis Payment Solutions is able to offer its StateSourced card on a state-by-state basis where the card can be used in purchasing product from a legal, authorized vendor, providing a much-needed option for consumers and businesses alike. In another first, the company is collaborating with First Bitcoin Capital Corporation to integrate First Bitcoin’s cryptocurrency ($Weed) with Medical Cannabis Payment Solutions’ StateSourced payment gateway. This collaboration will allow state-licensed marijuana establishments across the nation to accept both StateSourced debit cards and cryptocurrencies such as WeedCoin and Bitcoin.

Medical Cannabis Payment Solutions president and CEO Jeremy Roberts and his executive team are working with state lawmakers to introduce legislation in an effort to address the growing problems in banking for the medical cannabis industry. For companies in the emerging legal cannabis industry, where retail and non-retail transactions such as vendor payments and payroll are almost exclusively paid for with cash, the solutions offered by StateSourced can help businesses avoid the inherent risks associated with a cash-intensive sector. Medical Cannabis Payment Solutions has also signed its first StateSourced contract with a Las Vegas-based vertically integrated marijuana establishment.

“We’ve completed our transition from development stage to revenue stage,” says Roberts. “We have just started our business development efforts and the market is responding very well. We anticipate having many more, similar releases.”

Medical Cannabis Payment Solutions provides end-to-end management across multiple systems for medicinal marijuana operations. The company solves the fragmentation problem experienced by many of these rapidly growing companies by identifying tools that are important to dispensaries and customizing those tools to meet the specific needs of this unique industry.

Medical Cannabis Payment Solutions (REFG), closed the day's trading session at $0.019, off by 20.83%, on 226,751 volume with 23 trades. The average volume for the last 3 months is 462,980 and the stock's 52-week low/high is $0.0167/$0.092.

Recent News

chart

Cannabis Strategic Ventures, Inc. (NUGS)

The QualityStocks Daily Newsletter would like to spotlight Cannabis Strategic Ventures, Inc. (NUGS).

CannabisNewsAudio announces the Audio Press Release (APR) titled “Investors Flock to Cannabis Market as Business Booms,” featuring Cannabis Strategic Ventures (OTC: NUGS). To hear the CannabisNewsAudio version, visit: http://cnw.fm/6Rpdg. To read the full editorial, visit: http://cnw.fm/YSp6g. Also today, Cannabis Strategic Ventures is increasing its presence within the cannabis industry through a series of well-timed business building endeavors. To view the full article, visit: http://nnw.fm/g51JS.

Cannabis Strategic Ventures, Inc. (NUGS), headquartered in Los Angeles, California, is focused on supporting entrepreneurial growth within the fast-growing legal cannabis sector. Through a selective portfolio of subsidiaries, Cannabis Strategic Ventures offers outsourced personnel solutions tailor-made to match the growth dynamics of cannabis cultivators, manufacturers, dispensaries and other cannabis marketplace participants. The company also pursues investment opportunities in the areas of real estate, cultivation, extraction, distribution, packaging, dispensary operations, and branded products within the cannabis space.

The legalization of adult-use sales in California is expected to create nearly 99,000 cannabis industry jobs in the state by 2021, representing about a third of all cannabis jobs nationwide, and 146,000 jobs overall when indirect and induced efforts are considered, according to Arcview Market Research. By 2021, direct cannabis industry employment will top 291,500 FTE jobs, with a total employment effect of nearly 414,000 FTEs across all legal cannabis states, according to the report.

Cannabis Strategic Ventures believes its staffing capabilities will be in a similar state of demand. The company in April 2018 completed a definitive agreement to acquire Worldwide Staffing Group, Inc., which booked approximately $1.5 million in revenues in 2017.

Worldwide will operate within Cannabis Strategic Ventures as an independent and separate wholly owned subsidiary providing strictly non-cannabis related employment and staffing services. As Worldwide continues to expand its operations in general clerical and administrative, marketing, accounting, and other verticals, Cannabis Strategic Ventures will leverage the subsidiary’s expertise to expand its business operations further into the cannabis staffing arena, with an emphasis on the California markets.

Cannabis Strategic Ventures’ BudHire™ subsidiary is an outsourced employment service specifically designed to meet the needs of growing cannabis-related business operations, utilizes a proven recruiting formula to match the most qualified candidates to a broad spectrum of cannabis-related jobs. Under the BudHire™ brand, Cannabis Strategic Ventures offers temporary, seasonal, permanent staffing solutions, as well as professional employment organization services and human resources consulting to the cannabis industry.

Cannabis Strategic Ventures portfolio also includes Pure Applied Sciences Inc. and its brand “PureOrganix™,” a line of high quality concentrate, organic and pure cannabis oils that conform with Current Good Manufacturing Practices (cGMP) and meet FDA guidelines for Active Pharmaceuticals Products (API). The acquisition includes all intellectual properties, including formulations and technologies, and related accessories of Pure Applied Sciences.

Cannabis Strategic Ventures Pure Applied Sciences subsidiary, has a cannabis concentrate extraction services agreement with CP Logistics LLC (“CPL”), a wholly owned U.S. subsidiary of Sunniva Inc. (CSE:SNN) (OTCQX:SNNVF). Under this agreement, CPL will perform white label services producing high quality, ultra-purified cannabis extracts out of its Sun-Oil Facility in Cathedral City, California, for Pure Applied Sciences under the Pure Organix brand name.

The management team at Cannabis Strategic Ventures believes there is incredible opportunity to carve-out and control specific industry niches, to create unique cannabis consumer branded products, and to expand into other sub-sectors of the cannabis marketplace.

Cannabis Strategic Ventures, Inc. (NUGS), closed the day's trading session at $3.12, off by 15.09%, on 29,285 volume with 86 trades. The average volume for the last 3 months is 106,718 and the stock's 52-week low/high is $0.031/$7.13.

Recent News

chart

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

ActionStockPicksAgressive StocksBetting On Wall StreetCannabisNewsWireGot Stocks?Got Stock Tips?Green Car StocksGreen Energy StocksGreen On The StreetHomeRunStocksMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireQualityStocks MediaQStocksQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsStock BeatsStocks To Buy NowTerrificStocksTiny GemsTip.usTouchdownStocksDaily ToutTraderPower

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.